0001213900-23-054247.txt : 20230705 0001213900-23-054247.hdr.sgml : 20230705 20230703191124 ACCESSION NUMBER: 0001213900-23-054247 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230703 FILED AS OF DATE: 20230705 DATE AS OF CHANGE: 20230703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Altamira Therapeutics Ltd. CENTRAL INDEX KEY: 0001601936 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36582 FILM NUMBER: 231066331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON HM 11 STATE: D0 ZIP: 00000 BUSINESS PHONE: 41 (0) 41 729 71 94 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON HM 11 STATE: D0 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Auris Medical Holding Ltd. DATE OF NAME CHANGE: 20190318 FORMER COMPANY: FORMER CONFORMED NAME: Auris Medical Holding AG DATE OF NAME CHANGE: 20190314 FORMER COMPANY: FORMER CONFORMED NAME: Auris Medical Holding Ltd. DATE OF NAME CHANGE: 20190312 6-K 1 ea181306-6k_altamira.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2023

Commission File Number: 001-36582

Altamira Therapeutics Ltd.

(Exact name of registrant as specified in its charter)

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Reverse Share Split

As previously announced, on June 26, 2023, Altamira Therapeutics Ltd. (the “Company”) received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its common shares was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Deficiency”). The Company has a compliance period of 180 calendar days (the “Compliance Period”) to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company’s common shares is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In order to remediate the Bid Price Deficiency, in the event of the Company’s common share market price continues to not meet the $1.00 minimum bid price requirement, the Company intends to effect a reverse share split on or prior to July 31, 2023, at a ratio and at a time to be determined by the Company’s board of directors, taking into account the market price of the common shares at such time.

There can be no assurance that any reverse share split will cause the Company to regain compliance with the minimum bid price requirement, or that if the Company regains compliance it will maintain compliance with such requirement or the other continued listing requirements of Nasdaq.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Altamira Therapeutics Ltd.

	By:	/s/ Thomas Meyer
	Name:	Thomas Meyer
	Title:	Chief Executive Officer

Date: July 3, 2023